Press release
Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results
CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the
About this update from Organogenesis Holdings Inc.
[{"type":"text","content":"CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Summary: Net product revenue of $100.8 million for the second quarter of 2025, a decrease of $29.5 million compared to net product revenue of $130.2 million for the second quarter of 2024. Net product revenue for the second quarter of 2025 consists of: Net product revenue from Advanced Wound Care products of $92.7 million, a decrease of 25% from the second quarter of 2024.Net product revenue from Surgical & Sports Medicine products of $8.1 million, an increase of 16% from the second quarter of 2024. Net loss of $9.4 million for the second quarter of 2025, compared to a net loss of $17.0 million for the second quarter of 2024, a decrease in net loss of $7.6 million.Adjusted net loss of $7.5 million for the second quarter of 2025, compared to an adjusted net income of $0.2 million for the second quarter of 2024, a decrease in adjusted net income of $7.7 million.Adjusted EBITDA loss of $3.6 million for the second quarter of 2025, compared to Adjusted EBITDA income of $15.6 million for the second quarter of 2024, a decrease in Adjusted EBITDA income of $19.3 million. “I’m pleased with the team’s performance in the second quarter and our focus on helping customers navigate a disrupted environment; looking ahead, the policy changes expected in 2026 will be a watershed moment for the industry, bringing stability and creating opportunities to serve even more patients,” said Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board for Organogenesis. “We believe we are well-positioned to continue to be a leader in the industry with our comprehensive portfolio, including products from all FDA classifications and offer greater access to PMA products. Additionally, we remain confident in the transformational potential of ReNu for knee OA and look forward to sharing top line data from our second phase three study this September.” Second Quarter 2025 Financial Results: Three Months Ended June 30, Change 2025 2024 $ % (in thou...